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Background: Oxidative stress (OS) related to glucose degradation products such as methylglyoxal is reportedly
associated with peritoneal deterioration in patients treated with peritoneal dialysis (PD). However, the use of
general antioxidant agents is limited due to their harmful effects. This study aimed to clarify the influence of the
novel antioxidant molecular hydrogen (H2) on peritoneal OS using albumin redox state as a marker.
Methods: Effluent and blood samples of 6 regular PD patients were obtained during the peritoneal equilibrium test
using standard dialysate and hydrogen-enriched dialysate. The redox state of albumin in effluent and blood was
determined using high-performance liquid chromatography.
Results: Mean proportion of reduced albumin (ƒ(HMA)) in effluent was significantly higher in H2-enriched
dialysate (62.31 ± 11.10%) than in standard dialysate (54.70 ± 13.08%). Likewise, serum ƒ(HMA) after
administration of hydrogen-enriched dialysate (65.75 ± 7.52%) was significantly higher than that after standard
dialysate (62.44 ± 7.66%).
Conclusions: Trans-peritoneal administration of H2 reduces peritoneal and systemic OS.
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Peritoneal deterioration is one of the most serious com-
plications of peritoneal dialysis (PD) therapy, leading to
ultrafiltration failure and the more severe complication
of encapsulating peritoneal sclerosis (EPS). As the dur-
ation of PD increases, so does the risk of peritoneal de-
terioration [1]. More than 40% of patients in Japan who
were on PD treatment for longer than 8 years stopped it
due to the progression of peritoneal damage [2]. The
pathological mechanisms of peritoneal damage are
multi-factorial, but accumulated data have revealed the
critical role of glucose degradation end-products* Correspondence: masanaka@fmu.ac.jp
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reproduction in any medium, provided the or(GDPs), i.e., chemically reactive carbonyl compounds.
Methylglyoxal (MG) is one of the representative toxic
GDPs, causing detrimental effects due to its rapid and
indiscriminate oxidative nature [3], and its production
of toxic reactive oxygen species (ROS) such as hy-
droxyl radical, methyl radical, and undetermined carbon-
centered radicals [4]. These used to be present in
conventional dialysate, and also enter into the dialysate
from uremic plasma [5]. Bio-compatible low-GDP dialys-
ate is currently available, but a Japanese multicenter na-
tionwide study, the NEXT-PD study [6], revealed the
occurrence of EPS even with the use of low-GDP solutions
[under submission]. This indicates the need for novel
therapeutic approaches to suppress possible insults from
enhanced oxidative stress (OS) due to uremic oxidants in
the peritoneal cavity.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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an antioxidant has been revealed. H2 eliminates the hy-
droxyl radical in cultured cells and living organisms [7].
Interestingly, H2 does not influence other ROS, includ-
ing superoxide, peroxide, and nitric oxide; these ROS
play important physiological roles in body [8]. In
humans, the safety of H2 has been tested, particularly in
the field of deep diving. In contrast to general drugs,
which usually have some harmful effects, no toxicity was
found even at high concentrations of H2 [9]. H2 thus has
therapeutic potential for pathological states related to
ROS [10].
The present study tested the effects of peritoneal dialys-
ate containing a high concentration of molecular hydrogen
(H2-enriched dialysate) as a novel anti-oxidant among pa-
tients treated with PD. As a result, we demonstrated that
the use of hydrogen-enriched dialysate could reduce not
only peritoneal, but also systemic OS in clinical settings.
Methods
Preparation of hydrogen-enriched dialysate
Hydrogen-enriched dialysate was prepared using MiZ






Figure 1 MiZ nondestructive hydrogen dissolver (A) and the hydroge
water (B). Hydrogen concentration of dialysate and hydrogen-saturated wa
apparatus DH-35A (DKK-TOA, Tokyo, Japan).Japan), as reported elsewhere [11]. When commercial
peritoneal dialysate is immersed in H2-enriched water,
hydrogen permeates through the container, resulting in
the H2 concentration of dialysate gradually increasing
in a time-dependent manner (Figure 1). We prepared
H2-enriched dialysate using this apparatus by immers-
ing commercial peritoneal dialysate bags for more than
2 hr. Hydrogen-enriched dialysate was then applied as
a test solution for peritoneal equilibrium testing.
Patients
Six male PD patients were studied (mean age, 55 years;
range, 44–71 years; length of PD, 39 ± 17 months;
weight, 68.1 ± 16.1 kg; height, 166.2 ± 5.6 cm). The path-
ology underlying end-stage renal disease was as follows:
chronic glomerulonephritis, n = 3; diabetic nephropathy,
n = 2; and hypertensive nephropathy, n = 1. Patients with
active infection, bleeding, liver dysfunction, collagen dis-
ease, systemic vasculitis, cardiovascular accident within
6 months, or malignancy were excluded from this study.
Performance status of all patients was class 1 according
to American Heart Association criteria [12]. All pa-




n concentration of peritoneal dialysate in hydrogen-saturated
ter around dialysate was measured using a dissolved H2 measurement
Table 1 The changes of blood pressure, cardiac pulse,
and breath H2 concentration during fast PET
Standard dialysate H2-enriched dialysate
Blood pressure mmHg
0 min 130 ± 12 / 79 ± 10 135 ± 13 / 81 ± 10
60 min 130 ± 11 / 79 ± 5 131 ± 14 / 82 ± 12
120 min 125 ± 9 / 79 ± 7 134 ± 8 / 80 ± 14
180 min 123 ± 12 / 75 ± 12 136 ± 5 / 78 ± 12
240 min 128 ± 9 / 78 ± 7 132 ± 9 / 81 ± 13
Pulse /min
0 min 81 ± 7 82 ± 12
60 min 76 ± 6 79 ± 12
120 min 74 ± 6 78 ± 14
180 min 77 ± 4 78 ± 17
240 min 78 ± 7 81 ± 15
Breath H2 ppm
0 min 4.7 ± 6.6 3.2 ± 2.0
60 min 1.8 ± 1.3 8.3 ± 7.5*
120 min 3.0 ± 1.7 8.5 ± 11.0
180 min 4.2 ± 2.8 5.8 ± 4.8
240 min 5.5 ± 6.7 7.2 ± 4.6
*; p < 0.05 vs. standard dialysate.
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lution. The ethics committee of Fukushima Medical
University approved this study protocol (Acceptance
No. 1362) and written informed consent was obtained
from all patients prior to enrollment.
Protocol
Patients underwent a simplified peritoneal equilibration
test (fast PET) using standard dialysate, then underwent
fast PET using hydrogen-enriched dialysate 2 weeks
later. Fast PET was conducted in accordance with the
method of Twardowski [13]. In brief, peritoneal dialysate
(2 L of 2.5% dextrose-dialysate) was intraperitoneally in-
fused with a Tenckhoff catheter, and the entire volume
of dialysate was drained from the body after 240 min.
The drained effluent was mixed well and 2 mL was col-
lected as an effluent sample. Blood samples were
obtained before and after fast PET, then 2 mL of serum
was drawn after centrifugation and stored at −80°C for
1–4 weeks until analysis. Samples of serum and effluent
collected to measure albumin redox were stored at −80°C
for 1–4 weeks until analysis. During fast PET, blood
pressure, cardiac pulse, and hydrogen concentration
in the breath were measured repeatedly every 60 min.
Breath hydrogen concentration was also measured in
three cases just after, 15 min after, and 30 min after
infusion of H2-enriched dialysate. Breath hydrogen concen-
tration was measured using a biological gas (gas in the oral
cavity) H2 measurement apparatus BGA-1000D (Aptec,
Kyoto, Japan).
Measurement of albumin redox state
Human serum albumin (HSA) is a protein composed of
585 amino acids. The amino residue at position 34 from
the N-terminus is a cysteine, containing a mercapto
group (SH group). This mercapto group deoxidizes other
substances according to the degree of surrounding OS
and is itself oxidized. From the perspective of cysteine
residues, HSA is a mixture of human mercaptoalbumin
(HMA) in which the mercapto group is not oxidized,
human non-mercaptoalbumin-1 in which disulfide bond
formation is reversibly oxidized mainly by cysteine
(HNA-1), and human non-mercaptoalbumin-2 which is
strongly oxidized and forms a sulfinic (−SO2H) or sul-
fonic (−SO3H) group.
The redox state of HSA was determined using high-
performance liquid chromatography (HPLC), as previ-
ously reported [14]. The HPLC system consisted of an
autosampler (AS-8010; Tosoh, Tokyo, Japan; injection
volume, 2 μL) and double-plunger pump (CCPM;
Tosoh) in conjunction with a system controller (CO-
8011; Tosoh). Chromatographs were obtained using
a UV6000LP photodiode alley detector (detection
area, 200–600 nm with 1-nm step; Thermo Electron,Waltham, MA, USA). A Shodex-Asahipak ES-502N
7C column (10 × 0.76 cm I.D., DEAE-form for ion-
exchange HPLC; Showa Denko, Tokyo, Japan; column
temperature, 35 ± 0.5°C) was used in this study. Elusion
was performed as linear gradient elusion with graded etha-
nol concentrations (0 to 1 min, 0%; 1 to 50 min, 0→ 10%;
50 to 55 min, 10→ 0%; 55 to 60 min, 0%) for serum in
0.05 M sodium acetate and 0.40 M sodium sulfate mixture
(pH 4.85) at a flow rate of 1.0 mL/min. De-aeration of the
buffer solution was performed by bubbling helium.
HPLC profiles obtained from these procedures were
subjected to numerical curve fitting with PeakFit version
4.05 simulation software (SPSS Science, Chicago, IL,
USA), and each peak shape was approximated by a
Gaussian function. Values for fractions of HMA, HNA-1,
and HNA-2 to total HSA were then calculated (ƒ(HMA),
ƒ(HNA-1), and ƒ(HNA-2), respectively).Statistical analysis
Values are expressed as mean ± standard deviation un-
less otherwise stated. StatView version 5.0 statistical
software (SAS Institute, Cary, NC, USA) was used for
statistical analysis. The significance of collected data was
evaluated using a paired t-test or 1-factor repeated-
measures analysis of variance (ANOVA) followed by
Scheffe’s test as a post-hoc test, as appropriate. For mag-
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Figure 2 Change in breath hydrogen concentration during fast PET. A) Hourly change in PET using standard dialysate. No significant
changes were observed. B) Hourly change during PET using H2-enriched dialysate. The hydrogen concentration at 60 min was significantly higher
in H2-enriched dialysate than in standard dialysate. C) Breath hydrogen concentrations before, just after, 15 min after, and 30 min after
administration of H2-enriched dialysate in three cases. Hydrogen concentrations just after and 15 min after administration were significantly
higher than that before administration.
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ered significant for values of P < 0.05.
Results
Table 1 shows changes in blood pressure, heart rate, and
breath hydrogen concentration during fast PET. Regard-
ing blood pressure and heart rate, no significant differ-
ence was seen between standard and H2-enriched
dialysate (paired t-test). No significant changes were ob-
served during fast PET in either standard or H2-enriched
dialysate (1-factor repeated-measures ANOVA).
Changes in breath hydrogen concentration in all cases
are shown in Table 1 and Figure 2 (A, B). Although nosignificant changes were observed during fast PET in
both standard and H2-enriched dialysate, the hydrogen
concentration at 60 min was significantly higher in
H2-enriched dialysate than in standard dialysate.
Breath hydrogen concentrations before, just after,
15 min after, and 30 min after administration of H2-
enriched dialysate in three cases are shown in Figure 2C.
Hydrogen concentrations were significantly higher just
after and 15 min after administration (22.7 ± 5.7 and
15.3 ± 3.5 ppm, respectively) than before administra-
tion (4.0 ± 1.7 ppm).
Figure 3 shows the redox state of albumin in effluent

















































Figure 3 Redox state of albumin in effluent fluid. Mean
proportion of reduced albumin (ƒ(HMA)) was significantly higher
(A), and that of oxidized albumin (ƒ(HNA-1) (B) and ƒ(HNA-2))
(C) was significantly lower in H2-enriched dialysate than in
standard dialysate.
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11.10%) than in standard dialysate (54.70 ± 13.08%). In
contrast, ƒ(HNA-1) was significantly lower in H2-enricheddialysate (34.26 ± 10.24%) than in standard dialysate
(41.36 ± 12.04%). Like ƒ(HNA-1), ƒ(HNA-2) was signifi-
cantly lower in H2-enriched dialysate (3.43 ± 0.92%) than in
standard dialysate (3.94 ± 1.13%). These results suggest that
the use of H2-enriched dialysate reduced peritoneal OS.
Regarding the result of fast PET (D/P-Cre, drained volume)
and effluent creatinine, albumin, interleukin 6 and carbo-
hydrate antigen 125 levels, no differences were evident be-
tween standard and H2-enriched dialysate (Table 2).
Figure 4 shows the redox state of albumin in serum
before and after fast PET. The serum ƒ(HMA) level after
administration of H2-enriched dialysate (65.75 ± 7.52%)
was significantly higher than that after standard dialysate
(62.44 ± 7.66%). In contrast, ƒ(HNA-1) after administra-
tion of H2-enriched dialysate (31.12 ± 6.73%) was signifi-
cantly lower than that of standard dialysate (34.73 ±
7.02%). These results suggest that use of H2-enriched di-
alysate reduced not only peritoneal, but also systemic
OS. No significant difference was seen between effluent
and serum ƒ(HMA) levels after administration of
H2-enriched dialysate (65.31 ± 11.10% and 62.71 ±
7.52%, respectively), while effluent ƒ(HMA) after ad-
ministration of standard dialysate was significantly
lower than serum ƒ(HMA) before administration of
standard dialysate (54.70 ± 13.08% and 62.96 ± 8.34%,
respectively; P = 0.0339), suggesting that intraperitoneal
oxidation of albumin was suppressed by H2-enriched
dialysate.Discussion
Several reports have suggested that OS participates in
peritoneal deterioration, with findings such as strong
cytoplasmic staining of 8-hydroxy-2'-deoxyguanosine in
peritoneal biopsy specimens of long-term PD patients
[15], amplified protein kinase C signaling and fibronectin
expression due to enhanced ROS in cultured human
mesothelial cells [16]. In terms of the central role of en-
hanced OS in PD peritoneal damage, Gunal et al. [17]
showed that oral supplementation with the anti-
oxidative agent trimetazidine inhibited morphological
and functional deterioration of the peritoneum in a PD
rat model. However, regarding suppressing OS, no clin-
ical approaches have been available for PD treatment so
far.
The present study aimed to test the therapeutic possibil-
ity of using dissolved hydrogen in the dialysate to suppress
intra-cavity OS in the clinical setting. This study examined
the redox state of albumin as a marker of OS. Since the
change in redox state of albumin is a physiological and
direct reaction, it is appropriate when evaluating real-time
OS and/or detecting rapid changes in OS, as compared to
other OS markers such as 8-hydroxy-2'–deoxyguanosine,
oxidized low-density lipoprotein and F2 isoprotanes, all of






Creatinine mg/dL 10.53 ± 2.27 10.03 ± 2.19
Parameter of fast PET
D/P-Cre 0.71 ± 0.12 0.66 ± 0.11
Drained volume mL/4 hr 470 ± 184 442 ± 130
Effluent test
Albumin mg/L 408 ± 175 402 ± 145
Interleukin-6 pg/mL 6.0 ± 3.3 5.5 ± 2.3



























Figure 4 Redox state of albumin in serum before and after fast
PET. The mean proportion of reduced albumin (ƒ(HMA)) was
significantly higher after fast PET using H2-enriched dialysate than
after that using standard dialysate (A). Conversely, the mean
proportion of reversibly oxidized albumin (ƒ(HNA-1)) was
significantly lower after fast PET using H2-enriched dialysate than
that after using standard dialysate (B). No significant changes
were found in irreversibly oxidized albumin (ƒ(HNA-2)) in the
both groups (C).
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oxidation.
This pilot study of 6 patients clearly demonstrated that
single administration of H2-enriched dialysate increased
levels of both peritoneal and plasma ƒ(HMA) without
any detrimental effects.
Intraperitoneal administration of H2 altered the local
redox state, which may indicate the therapeutic potential
of delivering H2 directly to the abdominal cavity in re-
spect to the amelioration of peritoneal damage by PD
treatment. On the other hand, interestingly, significant in-
creases in serum ƒ(HMA) levels were seen on intraperito-
neal administration of H2. Rapid changes in hydrogen
concentration of expired gas after the administration of
H2-enriched dialysate may mean that molecular hydrogen
in dialysate is rapidly distributed to the body to suppress
systemic OS. Another possibility is that increased ƒ
(HMA) in the cavity may be recruited into systemic circu-
lation through the abdominal lymphatic drainage. The
exact mechanisms underlying increased serum ƒ(HMA)
need to be addressed in the future.
In addition, the mechanisms of increased ƒ(HMA) and
decreased ƒ(HMA1) by H2 have remained unclear in this
study. However, molecular hydrogen is known to directly
reduce levels of the cytotoxic hydroxyl radical [7], through
several possible mechanisms, such as regulation of par-
ticular metalloproteins by bonding, or metalloprotein-
hydrogen interactions [18]. Whether H2 directly reacts
with the mercapto-residue of albumin, or H2 indirectly
modifies it, should be clarified in the future.
Satisfactory anti-oxidative capability of drinking
H2-enriched water without any detrimental effects
has been reported, in both experimental [19-23] and
clinical settings, e.g., type II diabetes mellitus [24],
metabolic syndrome [25], myopathies (progressive
muscular dystrophy and polymyositis/dermatomyo-
sitis) [26], and rheumatoid arthritis [27]. In addition,
we also reported the clinical feasibility of applying
H2-enriched water as dialysate for hemodialysistreatment [28,29]. Given these reports and our
present findings, H2-enriched peritoneal dialysate could
be of interest in clinical trials with respect to peritoneal
preservation. Furthermore, therapeutic effects seem plaus-
ible in terms of the prevention of cardiovascular events in
patients, since low f(HMA) has been a significant risk fac-
tor for cardiovascular mortality among patients treated
with PD [30] and HD [14].
In summary, single administration of H2-enriched
dialysate reduced peritoneal and systemic OS without
any detrimental effects. A longitudinal study is war-
ranted to ensure clinically beneficial effects, such as
suppression of peritoneal deterioration and cardiovas-
cular damage.
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